BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32663767)

  • 21. The circadian clock is associated with prognosis and immune infiltration in stomach adenocarcinoma.
    Huang Z; He A; Wang J; Lu H; Zhang R; Wu L; Feng Q
    Aging (Albany NY); 2021 Jun; 13(12):16637-16655. PubMed ID: 34162762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated TUBA1A Might Indicate the Clinical Outcomes of Patients with Gastric Cancer, Being Associated with the Infiltration of Macrophages in the Tumor Immune Microenvironment.
    Wang D; Jiao Z; Ji Y; Zhang S
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):509-522. PubMed ID: 33331338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of an immune-related gene prognostic model for stomach adenocarcinoma.
    Wu M; Xia Y; Wang Y; Fan F; Li X; Song J; Ding J
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33112406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
    Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
    Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells.
    Miao L; Qi J; Zhao Q; Wu QN; Wei DL; Wei XL; Liu J; Chen J; Zeng ZL; Ju HQ; Luo HY; Xu RH
    Theranostics; 2020; 10(2):498-515. PubMed ID: 31903134
    [No Abstract]   [Full Text] [Related]  

  • 28. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
    Kim HN; Woo HY; DO SI; Kim HS
    In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels.
    Yang H; Li L; Liu X; Zhao Y
    Med Sci Monit; 2021 Feb; 27():e927977. PubMed ID: 33539329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
    Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages.
    Behring M; Vazquez AI; Cui X; Irvin MR; Ojesina AI; Agarwal S; Manne U; Shrestha S
    Mol Genet Genomic Med; 2019 Dec; 7(12):e1001. PubMed ID: 31637877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 36. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
    Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
    Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solute carrier family 35 member A2 (SLC35A2) is a prognostic biomarker and correlated with immune infiltration in stomach adenocarcinoma.
    Huang Z; Yang H; Lao J; Deng W
    PLoS One; 2023; 18(7):e0287303. PubMed ID: 37467193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype.
    Kim TS; da Silva E; Coit DG; Tang LH
    Am J Surg Pathol; 2019 Jun; 43(6):851-860. PubMed ID: 30969179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.